The mesolimbic system, denervation and the climbing response in the mouse

European Journal of Pharmacology
B CostallV Nohria

Abstract

Bilateral intra-accumbens 6-OHDA (2 micrograms in the presence of DMI and tranylcypromine, 14th postoperative day) enhanced the climbing responses of mice to apomorphine and 2-(N,N-dipropyl)amino-5,6-dihydroxytetralin causing parallel shifts of the normal log dose-response curves to the left. The enhancement of the apomorphine response was shown to be dependent on the dose of 6-OHDA, 0.5 micrograms being threshold and 2 micrograms maximum. Increased climbing was apparent by the 5th postoperative day, maximum by the 10th day, and was then maintained throughout the experimental period (6-8 weeks). 0.25-2 micrograms intra-accumbens 6-OHDA caused dose-related decreases in the dopamine content of mesolimbic areas (nucleus accumbens and tuberculum olfactorium) without causing significant changes in mesolimbic noradrenaline or striatal dopamine. In the absence of DMI/tranylcypromine, 2 and 4 micrograms 6-OHDA also decreased mesolimbic noradrenaline and striatal dopamine content. 16 micrograms 6-OHDA injected into the striatum (after DMI/tranylcypromine) decreased the striatal dopamine content by 85% (without altering mesolimbic dopamine or noradrenaline content) but this treatment failed to modify apomorphine climbing (2nd-12th postop...Continue Reading

References

Jun 15, 1979·European Journal of Pharmacology·B CostallV Nohria
Apr 1, 1976·European Journal of Pharmacology·A J PuechJ R Boissier
Apr 1, 1965·British Journal of Pharmacology and Chemotherapy·R LAVERTY, D F SHARMAN
Dec 1, 1964·International Journal of Neuropharmacology·C C CHANG

❮ Previous
Next ❯

Citations

Feb 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·P ProtaisJ C Schwartz
Jan 1, 1991·Journal of Neural Transmission. General Section·S K Bhattacharya, A P Sen
Jan 1, 1990·Psychopharmacology·C SchremmerT Ott
Sep 1, 1995·Psychopharmacology·S CabibS Puglisi-Allegra
Dec 10, 1985·European Journal of Pharmacology·J R Martin, A E Takemori
Oct 1, 1982·Pharmacology, Biochemistry, and Behavior·Y K FungD R Grassman
Jan 1, 1986·Pharmacology, Biochemistry, and Behavior·Y K FungN J Uretsky
Aug 2, 2002·Pharmacology, Biochemistry, and Behavior·Jun-ichi KarasawaKazutoshi Horikomi
Apr 18, 2009·Behavioural Brain Research·Susanne KootGiovanni Laviola
May 1, 1982·The Journal of Pharmacy and Pharmacology·J P GonzalezR D Sewell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here